<html>
<head>
  <title>2C9</title>
<style>
  .td {font-family: "verdana"; font-size: "10px"; color: "navy";}
  .green {background-color:"#ACA899";font-family:verdana; font-size:8pt;}
  .lite {background-color:"#F1EFE2";font-family:verdana; font-size:8pt; color:"#666600";}
  A:link {COLOR: "navy"; text-decoration: none;}
  A:visited {COLOR: "navy"; text-decoration: none;}
  A:active {COLOR: "navy"; text-decoration: none;}
  A:hover {COLOR:"#66CCFF";}
</style>
</head>

<body bgcolor="#FFFFFF">
<CENTER>
	<TABLE class="green" border="0" cellPadding="5" cellSpacing="1" width="600">

	
	<tr class="lite"><td>
	<b>References for Cytochrome P450 Drug Interaction Table</b><br>
	Part 4 of 7: 2C9 Isoform<br><br>
	

These pages contain all the literature citations referenced in the Cytochrome P450 Drug Interaction Tables (both the extensive <a HREF="index.htm">research-oriented table</a> and the concise <a HREF="clinlist.htm"> clinical table</a>). Most of these citations are hyperlinks, which bring up the abstract in the NLM's <i>PubMed<sup>®</sup></i> database.
	
<p>
Click on the <font COLOR="Blue"><i><u>PubMed</u></i></font> link after the drug name to perform a live MedLINE search of articles possibly related to that drug and
Cytochrome P450.</p>

<p>
Entries are organized by mode of activity (substrate, inhibitor, inducer)
within specific isoform. You can quickly branch to a section by clicking
on the appropriate link here:
</p>

<center>
  <table ALIGN="Center" cellpadding="5" cellspacing="1" border="0">
    <tr>
      <td class="td"><p ALIGN="Right">1A2:</td>
      <td class="td"><a HREF="1A2.htm#1A2sub">Substrates</a></td>
      <td class="td"><a HREF="1A2.htm#1A2inh">Inhibitors</a></td>
      <td class="td"><a HREF="1A2.htm#1A2ind">Inducers</a></td>
    </tr>
    <tr>
      <td class="td"><p ALIGN="Right">2B6:</td>
      <td class="td"><a HREF="2B6.htm#2B6sub">Substrates</a></td>
      <td class="td"><a HREF="2B6.htm#2B6inh">Inhibitors</a></td>
      <td class="td"><a HREF="2B6.htm#2B6ind">Inducers</a></td>
      </tr>
    <tr>
      <td class="td"><p ALIGN="Right">2C19:</td>
      <td class="td"><a HREF="2C19.htm#2C19sub">Substrates</a></td>
      <td class="td"><a HREF="2C19.htm#2C19inh">Inhibitors</a></td>
      <td class="td"><a HREF="2C19.htm#2C19ind">Inducers</a></td>
    </tr>
    <tr>
      <td class="td"><p ALIGN="Right">2C9:</td>
      <td class="td"><a HREF="2C9.htm#2C9sub">Substrates</a></td>
      <td class="td"><a HREF="2C9.htm#2C9inh">Inhibitors</a></td>
      <td class="td"><a HREF="2C9.htm#2C9ind">Inducers</a></td>
    </tr>
    <tr>
      <td class="td"><p ALIGN="Right">2D6:</td>
      <td class="td"><a HREF="2D6.htm#2D6sub">Substrates</a></td>
      <td class="td"><a HREF="2D6.htm#2D6inh">Inhibitors</a></td>
      <td class="td"><a HREF="2D6.htm#2D6ind">Inducers</a></td>
    </tr>
    <tr>
      <td class="td"><p ALIGN="Right">2E1:</td>
      <td class="td"><a HREF="2E1.htm#2E1sub">Substrates</a></td>
      <td class="td"><a HREF="2E1.htm#2E1inh">Inhibitors</a></td>
      <td class="td"><a HREF="2E1.htm#2E1ind">Inducers</a></td>
    </tr>
    <tr>
      <td class="td"><p ALIGN="Right">3A4,5,7:</td>
      <td class="td"><a HREF="3A457.htm#3A457sub">Substrates</a></td>
      <td class="td"><a HREF="3A457.htm#3A457inh">Inhibitors</a></td>
      <td class="td"><a HREF="3A457.htm#3A457ind">Inducers</a></td>
    </tr>
  </table>
  </center>

<p>
Hint: a quick way to find a specific reference on this page is to use your web browser's Search feature: press Ctrl-F and type all or part of the name or word for which you are searching.</p>
<p>
  <hr>

<a NAME="2C9sub"><img src="2C9substrates.jpg"></a>

<p>
<b><a NAME="31amitriptyline">amitriptyline:</a> </b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+amitriptyline&doptcmdl=DocSum">PubMed</a></i>
<p>
<b></b><i>Cytochrome P4502C9: an enzyme of major importance in human drug
metabolism.</i><br>
Miners JO, Birkett DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9663807&dopt=Abstract">Br
J Clin Pharmacol 1998 Jun;45(6):525-38 </a>
<p>
<a NAME="31celecoxib"><b>celecoxib:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+celecoxib&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="31candesartan"><b>NOT candesartan :</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+candesartan&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Candesartan cilexetil: a review of its preclinical pharmacology.</i><br>
Nishikawa K, Naka T, Chatani F, Yoshimura Y<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9330999&dopt=Abstract">J
Hum Hypertens 1997 Sep;11 Suppl 2:S9-S17</a>
<p>
<i>Pharmacokinetic drug interaction studies with candesartan
cilexetil.</i><br>
Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Hogemann
A<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9331003&dopt=Abstract">J
Hum Hypertens 1997 Sep;11 Suppl 2:S31-S35</a>
<p>
<i>Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan
cilexetil in healthy volunteers.</i><br>
van Lier JJ, van Heiningen PN, Sunzel M<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9331001&dopt=Abstract">J
Hum Hypertens 1997 Sep;11 Suppl 2:S27-S28</a>
<p>
<a name="31diclof"><b>diclofenac:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+diclofenac&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="31diclof"></a><i>In vivo inhibition profile of cytochrome
P450<sub>tb</sub> (CYP2C9) by (±)-fluvastatin.</i><br>
Transon C, Leemann T, Vogt N, Dayer P<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7586933&dopt=Abstract">Clin
Pharmacol Ther 1995;58(4):412-417</a>
<p>
<b><a NAME="31fluoxetine">fluoxetine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluoxetine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Cytochrome P4502C9: an enzyme of major importance in human drug
metabolism.</i><br>
Miners JO, Birkett DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9663807&dopt=Abstract">BrJ Clin Pharmacol 1998 Jun;45(6):525-38 </a>
<p>
<b><a NAME="31fluvastatin">fluvastatin:</a></b>
<font COLOR="Blue"><i><u><a HREF="http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?CMD=search&amp;DB=PubMed">PubMed</a></u></i></font>
<p>
<i>The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin:
effect on human cytochrome P-450 and implications for metabolic drug
interactions</i>.<br>
Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson
WT<font COLOR="Black"><br>
</font><font COLOR="Blue"><u><a HREF="http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10064574&amp;dopt=Abstract">Drug
Metab Dispos 1999 Mar;27(3):410-6</a></u></font>

<p>
<a name="glimepiride"><b>glimepiride</b></a>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+glimepiride&doptcmdl=DocSum">Pubmed</a></i>
</p>

<p>
<a NAME="glipizide"><b>glipizide:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+glipizide&doptcmdl=DocSum">PubMed</a></i>
</p>

<p>
<b><a NAME="31glyburide">glyburide:</a></b>
<font COLOR="Blue"><i><u><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+glyburide&doptcmdl=DocSum">PubMed</a></u></i></font>
<p>
<i>Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.</i>.<br>
Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C, Roots I.<font COLOR="Black"><br>
</font><font COLOR="Blue"><u><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11956512&dopt=Abstract">Clin Pharmacol Ther 2002 Apr;71(4):286-96</a></u></font>
</p>

<p>
<a name="31ibupro"><b>ibuprofen:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+ibuprofen&doptcmdl=DocSum">PubMed</a></i>

<p>
<a name="31ibupro"></a><i>Stereo- and nonstereospecific oxidation by
P450<sub>tb</sub> (CYP2C): The major elimination pathway of (+/-)
-ibuprofen.</i><br>
Leeman, T., Bonnabry, P., and Dayer, P<br>
Clin Pharmacol Ther 55:208, 1994
<p>
<a NAME="31irbesartan"><b>irbesartan:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+irbesartan&doptcmdl=DocSum">PubMed</a></i>
</p>



<p>
<a name="31losart"><b>losartan:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+losartan&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>A mutation in CYP2C9 is responsible for decreased metabolism of
losartan.</i><br>
Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman SA. Bjornnson T, Lo M-W,
Goldberg M<br>
Clin Pharmacol Ther 1996;59(2): 215 Abst.
<p>
<a NAME="31naproxen"><b>naproxen:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+naproxen&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic
O-demethylation of R- and S-naproxen.</i><br>
Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8866821&dopt=Abstract">Biochem
Pharmacol 1996 Apr 26;51(8):1003-1008</a>
</p>

<p>
<a name="nateglinide"><b>nateglinide</b></a>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+nateglinide&doptcmdl=DocSum">Pubmed</a></i>
</p>
<p>
<i>Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.</i><br>
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ.  <br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12968988&dopt=Abstract">Clin Pharmacol Ther. 2003 Oct;74(4):380-7</a>
</p>

<p>
<a name="31phenyt"><b>phenytoin:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+phenytoin&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver
cytochrome P4502C9.</i><br>
Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2025243&dopt=Abstract">Biochem
Biophys Res Commun. 1991;175(3):1112-1118</a>
<p>
<i>Fluconazole-induced symptomatic phenytoin toxicity.</i><br>
Cadle RM, Zenon GJ III, Rodriguez-Barradas MC, Hamill RJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8173131&dopt=Abstract">Ann
Pharmacother 1994;28(2) 191-194</a>
<p>
<a NAME="31piroxicam"><b>piroxicam:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+piroxicam&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Involvement of multiple cytochrome P450 isoforms in naproxen
O-demethylation.</i><br>
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR<i><br>
</i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9248768&dopt=Abstract">Eur
J Clin Pharmacol. 1997; 52(4): 293-298</a>
<p>
<i>Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting
the sole involvement of cytochrome P450 2C9.</i><br>
Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8937439&dopt=Abstract">Biochem
Pharmacol. 1996 Oct 25; 52(8): 1305-1309</a>
<p>
<a NAME="31rosiglitazone"><b>rosiglitazone:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+rosiglitazone&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="31suprofen"><b>suprofen:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+suprofen&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>The substrate binding site of human liver cytochrome P450 2C9: an approach
using designed tienilic acid derivatives and molecular modeling.</i><br>
Mancy A, Broto P, Dijols S, Dansette PM, Mansuy D<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7654690&dopt=Abstract">Biochemistry
1995 Aug 22;34(33):10365-10375</a>
<p>
<a name="31tamoxi"><b>tamoxifen:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+tamoxifen&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Delineation of human cytochromes P450 involved in the metabolism of
tamoxifen.</i><br>
Daniels, L., Blankson, E.A., Henderson, C.J., Harris, A.H., Wolf, C.R., Lennard,
M.S., and Tucker, G.T<br>
Br J Clin Pharmacol 33:153P, 1992
<p>
<a name="31torsem"><b>torsemide:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+torsemide&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="31torsem"></a><i>Human hepatic Cytochrome P450 catalyses the
rate-limiting pathway of torsemide metabolism.</i><br>
Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7891318&dopt=Abstract">J
Pharmacol Exp Ther 1995;272(3):1076-1081</a>
<p>
<a name="tolbutamide"><b>tolbutamide:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+tolbutamide&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="31tolbut"></a><i>Putative active site template model for cytochrome
P4502C9 (Tolbutamide hudroxylase).</i><br>
Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, Smith DA<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8742240&dopt=Abstract">Drug
Metabolism and Disposition 1996;24(2):260-266</a>
<p>
<a NAME="31valsartan"><b>NOT valsartan:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+valsartan&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Pharmacokinetics of valsartan in patients with liver disease.</i><br>
Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G,
Waldmeier F, Sioufi A, Mullins F<font COLOR="Blue"><br>
<u><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9333102&dopt=Abstract">Clinical
Pharmacology and Therapeutics, 62 (3) 272-278 1997</a></u></font>
<p>
<a name="31s-warf"><b>S-warfarin:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+warfarin&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Possible interaction between warfarin and fluconazole.</i><br>
Gericke KR<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8247921&dopt=Abstract">Pharmacotherapy
1993;13(5):508-509</a>
<p>
<i>Possible potentiation of warfarin by fluconazole.</i><br>
Seaton TL, Celum C.L., Black DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2089826&dopt=Abstract">Drug
Intelligence Clin Pharmacol 1990;24:1177-1178</a>
<p>
<i>Interactions of warfarin with drugs and food.</i><br>
Wells PS, Holbrook AM, Crowther NR, Hirsh J<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7944078&dopt=Abstract">Ann
Intern Med 1994;121:676-683</a>
<p>
<i>Inhibition of the human cytochrome P450- dependent metabolism of warfarin
by fluconazole: in vitro studies.</i><br>
Kunze KL, Wienkers LC, Thummel KE, Trager WF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8801056&dopt=Abstract">Drug
Metab Dispos 1996;24(4):414-421</a>
<p>
<i>A metabolically based drug interaction between fluconazole and warfarin:
in vivo studies.</i><br>
Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans
JS, Bauwens JE, Trager WF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8801057&dopt=Abstract">Drug
Metab Dispos 1996;24(4):422-428</a>
<p>
  <hr>
<a NAME="2C9inh"><img src="2C9inhibitors.jpg"></a>

<p>
<a name="32amioda"><b>amiodarone:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+amiodarone&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Mechanism of warfarin potentiation by amiodarone: dose--and
concentration-dependent inhibition of warfarin elimination.</i><br>
Almog S, Shafran N, Halkin H, Weiss P, Farfel Z, Martinowitz U, Bank H<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=4007030&dopt=Abstract">Eur
J Clin Pharmacol 1985;28:257-261</a>
<p>
<i>Steady-state interaction between amiodarone and phenytoin in normal
subjects.</i><br>
Nolan PE, Erstad BL, Hoyer GL, Bliss M, Gear K, Marcus FI<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2337037&dopt=Abstract">Am
J Cardiol 1990;65:1252-1257</a>
<p>
<a name="32flucon"><b>fluconazole:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluconazole&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32flucon"></a><i>Effect of fluconazole on the disposition of
phenytoin.</i> <br>
Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EU, Harrison NJ, Schentag
JJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2015731&dopt=Abstract">Clin
Pharmacol Ther 1991;49:420-425</a>
<p>
<a name="32fluvas"><b>fluvastatin:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluvastatin&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32fluvas"></a><i>In vivo inhibition profile of cytochrome
P450<sub>tb</sub> (CYP2C9) by (±)-fluvastatin.</i><br>
Transon C, Leemann T, Vogt N, Dayer P<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7586933&dopt=Abstract">Clin
Pharmacol Ther 1995;58(4):412-417</a>
<p>
<b><a NAME="32fluvoxamine">fluvoxamine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluvoxamine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro
studies with tolbutamide and (S)-warfarin using human liver
microsomes.</i><br>
Hemeryck A, De Vriendt C, Belpaire FM<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10192756&dopt=Abstract">Eur
J Clin Pharmacol 1999 Feb;54(12):947-51 </a>
<p>
<a name="32isonia"><b>isoniazid:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+isoniazid&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32isonia"></a><i>Clinical importance of the interaction of phenytoin
and isoniazid: a report of the Boston Collaborative Drug Surveillance
Program.</i><br>
Miller RR, Porter J, Greenblatt DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=421578&dopt=Abstract">Chest
1979;75(3):356-358</a>
<p>
<a name="32lovast"><b>lovastatin:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+lovastatin&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Warfarin Interaction.</i><br>
Ahmad S<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2241455&dopt=Abstract">Arch
Int Med 1990;150:2407-2408</a>
<p>
<a NAME="32paroxetine"><b>paroxetine:
</b></a><i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+paroxetine&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32phenyl"><b>phenylbutazone:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+phenylbutazone&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32phenyl"></a><i>Stereochemical aspects of warfarin drug interactions:
Use of a combinned pharmacokinetic- pharmacodynamic model.</i><br>
Chan E, McLachlan A, O'Reilly, Rowland M<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7924124&dopt=Abstract">Clin
Pharmacol Ther 1994;56(3):286-294</a>
<p>
<a name="32proben"><b>probenicid:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+probenicid&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Naproxen-probenecid interaction.</i><br>
Runkel R, Mroszczak E, Chaplin M, Sevelius H, Segre E<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=710028&dopt=Abstract">Clin
Pharmacol Ther 1978 Dec;24(6):706-713</a>
<p>
<a NAME="32sertraline"><b>sertraline:
</b></a><i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+sertraline&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32sulfameth"><b>sulfamethoxazole:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+sulfamethoxazole+AND+inhibitor&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32sulfameth"></a><i>Formation and disposition of sulfamethoxazole
hydroxylamine (SMX-MA).</i><br>
Spielberg SP, Nuss CE, Cribb AE<br>
Clin Pharmacol Ther 1995;57(2):221 Abst.
<p>
<a name="32sulpha"><b>sulfaphenazole:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+sulfaphenazole&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32sulpha"></a><i>In vitro inhibition studies of tolbutamide hydroxylase
activity of human liver microsomes by azoles, sulphonamides, and
quinolines.</i><br>
Back DJ, Tjia JF, Karbwang J, Colbert J<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3203057&dopt=Abstract">Br
J Clin Pharmacol 1988;26:23-29</a>
<p>
<a NAME="32teniposide"><b>teniposide:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+teniposide&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in
the CYP2C subfamily.</i><br>
Relling MV, Aoyama T, Gonzalez FJ, Meyer UA<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2299601&dopt=Abstract">J
Pharmacol Exp Ther 1990 Jan;252(1):442-7</a>
<p>
<a name="32ticlopidine"><b>ticlopidine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=ticlopidine+and+cyp2c9+AND+inhibitor&doptcmdl=DocSum">PubMed</a></i><br><br>
<i>Ticlopdine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19.</i><br>
Donahue SR, Flockhart DA, Abernethy DR, Ko JW<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9390115&dopt=Abstract">Br
Clin Pharmacol Ther 1997 Nov;62(5):572-7</a>
<p>
<a NAME="32trimethoprim"><b>trimethoprim:
</b></a><i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+trimethoprim&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="32zafirl"><b>zafirlukast:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+zafirlukast&doptcmdl=DocSum">PubMed</a></i>
<p>
(Accolate®) Prescriber's Letter 1996;3(10) 55. (October)
<p>
  <hr>

<a NAME="2C9ind"><img src="2C9inducers.jpg"></a>

<p>
<a NAME="33rifampin"><b>rifampin:
</b></a><i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+rifampin&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="33secobarbital"><b>secobarbital:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+secobarbital&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Stereochemical aspects of warfarin drug interactions: use of a combined
pharmacokinetic-pharmacodynamic model.</i><br>
Chan E, McLachlan A, O'Reilly R, Rowland M<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7924124&dopt=Abstract">Clin
Pharmacol Ther 1994 Sep;56(3):286-294</a>
</body></html>
